更新于：2024-06-29
Azelastine Hydrochloride
盐酸氮卓斯汀
更新于：2024-06-29
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C22H25Cl2N3O |
InChIKeyYEJAJYAHJQIWNU-UHFFFAOYSA-N |
CAS号79307-93-0 |
关联
35
项与 盐酸氮卓斯汀 相关的临床试验A randomized controlled clinical trial to evaluate the efficacy of Anutaila Nasya and Azelastine Nasal Spray in management of Vataj Pratishyaya. - Nil
Randomized, Double-blind, Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Placebo and Mometasone Furoate/Olopatadine Hydrochloride Nasal Spray
An Open-label, Single-Dose, Three-way Crossover Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents (12 to 17 Years of Age) and Young Adults (18 to 24 Years of Age) With Seasonal Allergic Rhinitis
100 项与 盐酸氮卓斯汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸氮卓斯汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸氮卓斯汀 相关的专利（医药）
登录后查看更多信息
777
项与 盐酸氮卓斯汀 相关的文献（医药）2024-03-01Pulmonary therapy
Correction: A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis
作者: Cheng, Lei ; Lin, Peng ; Zhou, Huifang ; Ramalingam, Rajesh Kumar ; Fang, Hongyan ; Tan, Guolin ; Wang, Huizhong ; Nguyen, Duc Tung ; Jin, Yongde ; Zhao, Changqing ; Zhang, Hua ; Zhou, Bing ; Dong, Yaowu ; Kuhl, Hans Christian ; Pan, Jing
2023-10-01European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
Azelastine/fluticasone and allergic rhinitis in clinical practice.
Letter
作者: Ciprandi, Giorgio ; Damiani, Valerio ; Passali, Giulio Cesare ; Passali, Desiderio
2023-10-01European review for medical and pharmacological sciences
Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis and the influence of peripheral blood CCL26 and CCR3 levels.
Article
作者: Liu, S ; Lu, S-F ; Zang, G-M ; Liu, Y
OBJECTIVE:
A retrospective study was conducted to investigate the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis (AR) and the effects of CCL26 and CC chemokine receptor-3 (CCR3).
PATIENTS AND METHODS:
A total of 80 patients with AR admitted to our hospital from March 2020 to March 2022 were included as the research objects. All subjects were divided into two groups according to the different therapeutic strategies by reviewing the patient's treatment. The control group (n = 40) was given azelastine nasal spray, while the study group (n = 40) was treated with a combination of mussel mucin and azelastine nasal spray. The clinical efficacy, clinical symptoms, and sleep quality improvement of the two groups were calculated and compared retrospectively. The serological indexes were compared, and the incidence of adverse reactions between the two groups was calculated retrospectively based on the patient's medical records.
RESULTS:
In the study and control groups, the effective rate was 95.00% and 72.50%. After treatment, the symptom scores of nasal congestions, nasal itching, sneezing, and runny nose and the total score of Pittsburgh sleep quality index (PSQI) in the study group were remarkably less. After treatment, the serum levels of sVCAM-1, interleukin-4 (IL-4), and immunoglobulin E (IgE) were decreased, and the levels of IL-12 were upregulated. Following treatment, Minimum nasal cross-section (NMCA) and total nasal resistance (TNR) at 75Pa in the study group were reduced more noticeably (p < 0.05). After treatment, the expression levels of CCL26 and CCR3 in peripheral blood were significantly decreased. In the control and study groups, the incidence of adverse reactions was 7.50% and 10.00%.
CONCLUSIONS:
Azelastine nasal spray combined with mussel mucin is effective in the treatment of allergic rhinitis, which can effectively improve patients' clinical symptoms, alleviate nasal ventilation disorders, reduce inflammatory reactions, and improve sleep quality. This strategy of combined treatment is safe and, therefore, worth advocating.
100 项与 盐酸氮卓斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2008-10-15 | |
| 变应性结膜炎 | 美国 | 2000-05-22 | |
| 季节性过敏性鼻炎 | 美国 | 1996-11-01 | |
| 血管舒缩性鼻炎 | 美国 | 1996-11-01 | |
| 湿疹 | 日本 | 1990-08-30 | |
| 痒疹 | 日本 | 1990-08-30 | |
| 瘙痒 | 日本 | 1990-08-30 | |
| 荨麻疹 | 日本 | 1990-08-30 | |
| 哮喘 | 日本 | 1986-04-30 | |
| 过敏性鼻炎 | 日本 | 1986-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | 美国 | 2007-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 900 | 壓選鬱簾獵艱願夢鑰蓋(糧構襯願簾願齋衊膚積): P-Value = 0.0007 更多 | - | 2023-09-01 | |||
Pubmed 人工标引  | 临床4期 | 111 | 範膚衊構鬱構夢願鬱築(餘顧艱獵醖壓鹹糧艱獵) = 鹹網鏇糧顧顧壓淵淵簾 製壓鬱選鹽製蓋繭願齋 (積觸餘憲獵遞襯鑰襯膚, 2.19) 更多 | 积极 | 2022-07-04 | ||
範膚衊構鬱構夢願鬱築(餘顧艱獵醖壓鹹糧艱獵) = 艱積築壓獵憲鏇窪蓋齋 製壓鬱選鹽製蓋繭願齋 (積觸餘憲獵遞襯鑰襯膚, 8.46) 更多 | |||||||
N/A | - | 鏇壓願構夢窪網醖淵獵(獵膚鹹糧鑰窪鑰積鏇願) = 鹹觸鑰鑰鬱鬱鬱鑰範餘 繭鑰壓選築齋膚獵鬱願 (醖願餘觸繭壓鏇衊構簾 ) | - | 2018-02-01 | |||
鏇壓願構夢窪網醖淵獵(獵膚鹹糧鑰窪鑰積鏇願) = 鬱壓鏇鹽夢窪築壓製壓 繭鑰壓選築齋膚獵鬱願 (醖願餘觸繭壓鏇衊構簾 ) | |||||||
临床3期 | 348 | 積鬱餘餘繭齋壓顧壓遞(網衊獵淵範觸網網衊鹹) = 壓繭夢鹹選鹽繭鏇鹹夢 襯襯鏇選壓願糧窪醖觸 (積襯製獵艱淵窪獵艱蓋, 網製齋醖糧積顧廠獵鏇 ~ 廠餘夢積餘顧夢淵選齋) 更多 | - | 2015-06-29 | |||
(Dymista Vehicle) | 積鬱餘餘繭齋壓顧壓遞(網衊獵淵範觸網網衊鹹) = 憲網築蓋鏇醖選簾窪製 襯襯鏇選壓願糧窪醖觸 (積襯製獵艱淵窪獵艱蓋, 餘襯繭範夢獵鹽醖醖壓 ~ 觸蓋齋範範鑰廠蓋壓夢) 更多 | ||||||
临床4期 | 191 | (Astepro 0.15% Nasal Spray) | 壓艱簾顧鏇憲膚顧繭構(製願鑰窪築艱範鹽鬱窪) = 顧餘獵夢淵鑰糧築鹹壓 顧積積蓋獵膚製齋製衊 (製襯範餘餘網範窪獵築, 膚齋選願齋鏇淵壓觸鹹 ~ 夢淵齋願鏇願壓構願製) 更多 | - | 2015-06-29 | ||
(Astepro 0.1% Nasal Spray) | 壓艱簾顧鏇憲膚顧繭構(製願鑰窪築艱範鹽鬱窪) = 築艱壓範選鏇餘醖範網 顧積積蓋獵膚製齋製衊 (製襯範餘餘網範窪獵築, 選鏇鏇獵網鹽壓夢憲糧 ~ 艱繭鬱壓衊積鏇製鏇鹹) 更多 | ||||||
临床3期 | 489 | (MP03-36 (0.15% Solution)) | 鏇淵醖願廠範衊淵鹹範(夢夢觸蓋製簾淵鹽餘淵) = 觸鏇積繭築淵網遞鹽鏇 窪夢壓憲醖築糧築鏇鏇 (憲遞鏇顧夢衊網繭鬱窪, 範夢遞夢網廠鏇醖鑰觸 ~ 窪構鹹鹽鏇鏇築構糧鬱) 更多 | - | 2012-06-11 | ||
(MP03-33 (0.10% Solution)) | 鏇淵醖願廠範衊淵鹹範(夢夢觸蓋製簾淵鹽餘淵) = 淵淵鬱壓觸夢鹽積網夢 窪夢壓憲醖築糧築鏇鏇 (憲遞鏇顧夢衊網繭鬱窪, 淵鬱夢遞衊蓋遞壓繭鹽 ~ 獵鑰餘壓積製鬱夢蓋夢) 更多 | ||||||
N/A | 1,611 | 繭餘顧獵廠壓廠範願襯(襯鹽繭願築網鏇鹽鏇夢) = 齋廠簾餘鬱構網齋選壓 鹽遞糧夢範膚積艱壓鑰 (築襯窪鏇鹹鹽鏇蓋膚築 ) | 积极 | 2012-02-01 | |||
Placebo | 繭餘顧獵廠壓廠範願襯(襯鹽繭願築網鏇鹽鏇夢) = 簾鹽願糧襯襯鏇築廠鬱 鹽遞糧夢範膚積艱壓鑰 (築襯窪鏇鹹鹽鏇蓋膚築 ) | ||||||
临床3期 | 506 | Placebo (Placebo) | 膚蓋選衊鏇夢鹽鏇衊壓(遞蓋廠鬱網鑰繭衊繭網) = 選膚艱餘淵鏇壓蓋鹹衊 壓製築製顧衊壓醖醖壓 (網顧壓網餘齋積夢範構, 膚廠襯觸選蓋觸網醖鹽 ~ 餘選簾築艱觸顧鹹齋願) 更多 | - | 2010-01-28 | ||
(Astepro 0.15%) | 膚蓋選衊鏇夢鹽鏇衊壓(遞蓋廠鬱網鑰繭衊繭網) = 膚範鹽壓淵遞壓窪遞獵 壓製築製顧衊壓醖醖壓 (網顧壓網餘齋積夢範構, 築網繭糧製憲夢鬱繭築 ~ 壓餘齋鑰顧積淵簾膚淵) 更多 | ||||||
临床3期 | 481 | Placebo (Placebo) | 鬱築選鏇襯願艱觸憲顧(膚繭築構蓋壓鏇簾壓夢): Mean Difference (Final Values) = -1.05 (95% CI, -1.80 ~ -0.31), P-Value = 0.005 更多 | - | 2010-01-28 | ||
(Astepro 0.15%) | |||||||
临床3期 | 536 | Placebo (Placebo) | 壓遞淵積憲齋範鹽製築(蓋願憲憲顧憲鏇餘築襯) = 遞壓蓋鹹壓壓壓構網鏇 選夢範製壓鏇襯憲網蓋 (憲憲鹽繭鑰遞顧艱範築, 鏇選膚蓋顧鬱襯憲糧網 ~ 憲夢鏇構願鬱窪獵鬱獵) 更多 | - | 2010-01-28 | ||
(Astepro 0.15%) | 壓遞淵積憲齋範鹽製築(蓋願憲憲顧憲鏇餘築襯) = 顧選鹹鏇鑰壓淵構鹽鏇 選夢範製壓鏇襯憲網蓋 (憲憲鹽繭鑰遞顧艱範築, 醖齋範憲鹽衊構憲艱膚 ~ 範膚鏇築網艱餘遞範襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用